2014 Plasminogen Activation and Extracellular Proteolysis Gordon Research Confere
2014年纤溶酶原激活和细胞外蛋白水解戈登研究会议
基本信息
- 批准号:8651027
- 负责人:
- 金额:$ 0.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-02-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAlteplaseAlzheimer&aposs DiseaseAreaBasic ScienceBiological MarkersBiologyBiomedical EngineeringBlood VesselsCardiovascular PhysiologyCardiovascular systemCell physiologyClinical ResearchCollaborationsDeep Vein ThrombosisDevelopmentDisciplineDiseaseDrug Delivery SystemsEnvironmentFunctional disorderFundingFunding ApplicantGoalsHematopoiesisHomeostasisImageInternationalLeadLocationMalignant NeoplasmsMediatingMediator of activation proteinMetabolismMethodologyModalityMyocardial InfarctionNatural regenerationNervous System PhysiologyNeuraxisObesityParticipantPathologic ProcessesPeptide HydrolasesPhysiological ProcessesPlasminogenPostdoctoral FellowProcessProteolysisResearchResearch PersonnelRoleScientistStrokeSystemTherapeuticTissuesTranslatingTranslationsTraumatic Brain InjuryTumor BiologyUnderrepresented MinorityWomanangiogenesisbioimagingexperienceextracellularfrontiergraduate studenthuman diseaseinhibitor/antagonistinnovationinsightinterdisciplinary approachmeetingsnovelnovel therapeutic interventionpeerposterspublic health relevancereceptorstem cell biologysymposium
项目摘要
DESCRIPTION (provided by applicant): Funds are sought for partial support of the 2014 Plasminogen Activation and Extracellular Proteolysis Gordon Research Conference (GRC) and Gordon Research Seminar (GRS). These are paired conferences held sequentially at the same location, February 8-9, 2012 for the GRS, and February 9-14 for the GRC. The GRC has been held continuously every two years since 1990 and enjoys an outstanding international reputation. It brings together a group of highly motivated participants with diverse scientific backgrounds that engage in intensive, yet informal, discussions at the frontier of research related to the plasminogen activation system and associated extracellular proteases in an "off-the-record" fashion. The conference thus provides a unique opportunity for the leading researchers in the world from a broad range of disciplines to present their latest unpublished research related to plasminogen activation and extracellular proteolysis, and to discuss innovative ways to translate their research into new therapies. Previous research in our field has led to the development of tissue plasminogen activator (tPA) for the successful treatment of a wide range of thromboembolic disorders, and the discovery of important roles for the plasminogen activation system extracellular proteolysis in a number of physiologic and pathologic processes. In the 2014 meeting, emphasis will be placed on Mechanisms, Imaging, and Therapeutics. The 2014 GRC will be launched by our Keynote Speaker Roger Tsien, Nobel Laureate for the discovery of GFP, who will discuss novel protease probes. Breakthrough findings in plasminogen activation and extracellular proteolysis in vascular biology, central nervous system function and dysfunction, traumatic brain injury, Alzheimer's disease, tissue homeostasis and regeneration, hematopoiesis, stem cell biology, metabolism and obesity, tumor biology, cardiovascular function, and angiogenesis will be discussed. Novel modalities of biomedical imaging and bioengineering in the field of proteases will be presented. Since translating basic research into treatments is a major focus of the 2014 meeting, the cutting- edge in biomarkers, drug delivery, and new therapies in our field will be discussed. Attendees will be selected by invitation and from applications submitted online. They will be chosen to represent a diverse spectrum of researchers, and a strong emphasis has been made on the inclusion of women and underrepresented minorities as Discussion Leaders and Speakers, and will continue on Poster Presenters, and Attendees. The associated GRS is a novel feature that will provide a unique opportunity for young scientists to share in the GRC experience. This two-day seminar will be organized by Graduate Students and Postdoctoral Fellows with the support of leading researchers, and will allow junior researchers within the field of plasminogen activation and extracellular proteolysis to come together to discuss their current research, while building informal networks with their peers that may lead to a lifetime of collaboration and scientific achievement.
描述(由申请人提供):资金寻求2014年纤溶酶原激活和细胞外蛋白质水解戈登研究会议(GRC)和戈登研究研讨会(GRS)的部分支持。这些是在同一地点顺序举行的配对会议,2012年2月8日至9日为GRS,2月9日至14日为GRC。自1990年以来,GRC每两年连续举办一次,在国际上享有盛誉。它汇集了一群具有不同科学背景的高度积极性的参与者,他们以“非正式”的方式在与纤溶酶原激活系统和相关细胞外蛋白酶相关的研究前沿进行了深入而非正式的讨论。因此,会议为来自广泛学科的世界领先研究人员提供了一个独特的机会,展示他们与纤溶酶原激活和细胞外蛋白水解相关的最新未发表的研究,并讨论将他们的研究转化为新疗法的创新方法。本领域先前的研究已经导致开发了组织纤溶酶原激活剂(tPA)用于成功治疗广泛的血栓栓塞性疾病,并且发现纤溶酶原激活系统细胞外蛋白水解在许多生理和病理过程中的重要作用。在2014年的会议上,重点将放在机制,成像和治疗。2014年GRC将由我们的主题演讲人Roger Tsien启动,他是发现GFP的诺贝尔奖获得者,他将讨论新型蛋白酶探针。本课程将讨论纤溶酶原激活和细胞外蛋白水解在血管生物学、中枢神经系统功能和功能障碍、创伤性脑损伤、阿尔茨海默病、组织稳态和再生、造血、干细胞生物学、代谢和肥胖、肿瘤生物学、心血管功能和血管生成中的突破性发现。将介绍蛋白酶领域的生物医学成像和生物工程的新模式。由于将基础研究转化为治疗方法是2014年会议的主要焦点,因此将讨论我们领域的生物标志物,药物输送和新疗法的前沿。与会者将通过邀请和在线提交的申请进行选择。他们将被选为代表不同领域的研究人员,并大力强调将妇女和代表性不足的少数民族作为讨论领导人和发言人,并将继续作为海报展示者和与会者。相关的GRS是一项新颖的功能,将为年轻科学家提供分享GRC经验的独特机会。这个为期两天的研讨会将由研究生和博士后研究员在领先研究人员的支持下组织,并将允许纤溶酶原激活和细胞外蛋白水解领域的初级研究人员聚集在一起讨论他们目前的研究,同时与同行建立非正式网络,这可能会导致终身的合作和科学成就。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katerina Akassoglou其他文献
Katerina Akassoglou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katerina Akassoglou', 18)}}的其他基金
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
9765418 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
10224346 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
10019602 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
10673069 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
10477958 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
神经血管相互作用:机制、成像、治疗潜力
- 批准号:
9553871 - 财政年份:2016
- 资助金额:
$ 0.5万 - 项目类别:
Mechanisms of Fibrin Action in Neuronal Functions
纤维蛋白在神经元功能中的作用机制
- 批准号:
8715494 - 财政年份:2014
- 资助金额:
$ 0.5万 - 项目类别:
Mechanisms of Fibrin Action in Neuronal Functions
纤维蛋白在神经元功能中的作用机制
- 批准号:
8815340 - 财政年份:2014
- 资助金额:
$ 0.5万 - 项目类别:
Mechanisms and functions of p75 neurotrophin receptor signaling in astrocytes
星形胶质细胞中 p75 神经营养蛋白受体信号传导的机制和功能
- 批准号:
8518998 - 财政年份:2012
- 资助金额:
$ 0.5万 - 项目类别:
MICROGLIA ACTIVATION IN RESPONSE TO BLOOD-BRAIN BARRIER DISRUPTION IN THE CNS
小胶质细胞激活对中枢神经系统血脑屏障破坏的反应
- 批准号:
8361913 - 财政年份:2011
- 资助金额:
$ 0.5万 - 项目类别:
相似海外基金
AcT-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (AcT) trial.
AcT-Cog:阿替普酶与替奈普酶 (AcT) 试验相比的在线认知评估。
- 批准号:
444794 - 财政年份:2021
- 资助金额:
$ 0.5万 - 项目类别:
Operating Grants
INTERRAcT: Thrombus characteristics for predicting Reperfusion with Alteplase compared to Tenecteplase
INTERRAcT:与替奈普酶相比,阿替普酶预测再灌注的血栓特征
- 批准号:
433102 - 财政年份:2020
- 资助金额:
$ 0.5万 - 项目类别:
Operating Grants
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial
阿替普酶与替奈普酶治疗急性缺血性中风患者的比较:QuICR
- 批准号:
401715 - 财政年份:2019
- 资助金额:
$ 0.5万 - 项目类别:
Operating Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
- 批准号:
nhmrc : 1079696 - 财政年份:2015
- 资助金额:
$ 0.5万 - 项目类别:
Project Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
- 批准号:
nhmrc : GNT1079696 - 财政年份:2015
- 资助金额:
$ 0.5万 - 项目类别:
Project Grants
Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study
低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风:一项基于影像学的安全性和有效性研究
- 批准号:
nhmrc : 510722 - 财政年份:2008
- 资助金额:
$ 0.5万 - 项目类别:
NHMRC Project Grants
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
8565339 - 财政年份:
- 资助金额:
$ 0.5万 - 项目类别:
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
7593114 - 财政年份:
- 资助金额:
$ 0.5万 - 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
- 批准号:
8952839 - 财政年份:
- 资助金额:
$ 0.5万 - 项目类别:














{{item.name}}会员




